Balcer, L J <br/><br/>
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.  [electronic resource] 

 -  Neurology  Apr 2007 
 - 1299-304 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1526-632X 
<br/><br/><label>Standard No.: </label>10.1212/01.wnl.0000259521.14704.a8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Brain--drug effects<br/>Contrast Sensitivity--drug effects<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--complications<br/>Natalizumab<br/>Neurologic Examination--methods<br/>Placebos<br/>Predictive Value of Tests<br/>Treatment Outcome<br/>Vision Tests--methods<br/>Vision, Low--drug therapy<br/>Visual Acuity--drug effects<br/>Visual Pathways--drug effects